Oragenics Revenue and Competitors
Estimated Revenue & Valuation
- Oragenics's estimated annual revenue is currently $3.5M per year.
- Oragenics's estimated revenue per employee is $194,444
- Oragenics's total funding is $98.8M.
Employee Data
- Oragenics has 18 Employees.
- Oragenics grew their employee count by -10% last year.
Oragenics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.6M | 81 | 5% | N/A | N/A |
#2 | $1.4M | 6 | -25% | N/A | N/A |
#3 | $3.6M | 20 | 5% | N/A | N/A |
#4 | $4.5M | 23 | -4% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.9M | 4 | 0% | N/A | N/A |
#7 | $1.4M | 6 | 0% | N/A | N/A |
#8 | $3.7M | 13 | 8% | N/A | N/A |
#9 | $2.5M | 7 | -30% | N/A | N/A |
#10 | $0.9M | 3 | 0% | N/A | N/A |
What Is Oragenics?
Oragenics is a publicly held biopharmaceutical company trading on the American Stock Exchange under the symbol ONI and on the Toronto Stock Exchange\'s (TSX) Venture Exchange under the symbol ORA.U. The company is located in Progress Corporate Park in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville. Our corporate strategy is aimed at adding value to novel technologies and products sourced from innovative research at the University of Florida and other academic centers. Our aim is to develop products through human proof-of-concept (Phase I or II of the FDA\'s regulatory process) prior to partnering with major pharmaceutical, biotechnology or healthcare product firms for advanced clinical development and commercialization.
keywords:N/A
$98.8M
Total Funding
18
Number of Employees
$3.5M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oragenics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer And Interim Principal Executive Officer | Reveal Email/Phone |
2 | Junior Research Scientist, R&D | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | President, CEO | Reveal Email/Phone |
Oragenics News
(NYSE American: OGEN) (Oragenics or the Company), a biotech company dedicated to fighting infectious diseases including coronavirus, today...
Development stage biotech, Oragenics (OGEN -10.5%) has recorded the biggest intraday loss in a year on Friday after the company said that...
By Colin Kellaher. Oragenics Inc. said its auditor has expressed substantial doubt about the biopharmaceutical company's ability to continue...
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum TAMPA, Fla. (November 23, 2021) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced that the Company's Annual Meeting of Shareholders (the "Annual Meeting"), on November 22, 202 ...
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum TAMPA, Fla. (July 1, 2021) - Oragenics, Inc. (NYSE American: OGEN) ('Oragenics' or the 'Company') announced that the Company's annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and ...
Other Companies in Town n Country
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 29 | 0% | N/A |
#2 | $10.7M | 37 | 12% | N/A |
#3 | $4.8M | 45 | 13% | $1.8M |
#4 | $21.3M | 46 | -6% | N/A |
#5 | $5.7M | 59 | 7% | N/A |